POZ - IAS 2011 - International AIDS Society

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
HIGHLIGHTS
What you need to know
> Blogs > POZ Exclusives > Treatment News > Video


Going the Distance

Isentress comparable to Sustiva over five years of treatment.



Treatment as Prevention in People with HIV

Full results of the HPTN 052 study at IAS 2011 confirm ARVs reduce HIV risk by 96 percent for heterosexual couples.



Female Power

Genital secretions from women with HIV using ARVs contain high drug concentrations and low amounts of virus.



No Bones
About It

Traditional risk factors for fractures—race, aging, smoking and diabetes—are much greater contributors than HIV meds.



IAS in Rome

Check out the IAS 2011 website for a comprehensive roundup of the current conference.


Say What?

Hearing loss tied to age, gender, race; not HIV.



Truvada as
HIV Prevention

Preliminary data from the Partners PrEP study at IAS 2011 "definitively" show reduced HIV risk for mixed-status heterosexual couples.



Early Treatment Reduces Serious Illness

Starting ARVs once a CD4 count falls below 550 was associated with a 40 percent reduction in the risk of serious illness in HPTN 052.



Science Only Half the Battle

IAS 2011 organizers warn discoveries only matter if they can effectively be rolled out evenly across the world.



IAS Journal

The Journal of the International AIDS Society provides a forum for HIV-related research.


A Shore Thing

Testing for HIV in NJ emergency rooms works.



Strategy for
the Cure

IAS 2011 leadership calls for accelerated research toward a cure for HIV—and they want your help.



Racking
Your Brain

Drugs known to penetrate the central nervous system do not offer much more protection against neuropsychological problems associated with HIV.



Transplant Survival

Survival is "excellent" among people living with HIV undergoing kidney transplants.



DC in 2012

For updates on the next International AIDS Conference in Washington, DC, go to the AIDS 2012 website.

NEWSFEED
Coverage from
AIDSmeds & POZ

Hearing Loss Tied to Age, Gender, Race; Not HIV

Norvir-Boosted Reyataz Comparable in HIV-Positive Women Versus Men

PrEP in iPrEx: 92% Fewer Infections in Those With Detectable Drug Levels

New Jersey: Emergency Room HIV Testing Works

Five-Year Follow-Up: Isentress Comparable to Sustiva

Selzentry Reduces Liver Stiffness in HIV/HCV-Coinfected Patients

Edurant and Sustiva Similar, With Some Failure and Safety Differences, in Two-Year Studies

Hormone-Based Birth Control Raises HIV Risk

VIRxSYS Vaccine 'Functionally' Cures Two Monkeys in Recent Study

HIV Treatment Works in Female Genital Tract

Brain-Penetrating ARVs Don't Improve HIV Neuro Problems, Says Ontario Study

Elvitegravir Proving Comparable to Isentress in HIV Treatment Veterans

PrEP Cuts Sexual HIV Transmissions 62% to 78% in Men and Women

Early Treatment Reduces Serious Illnesses by 40% in HPTN 052

Non-Nuke Lersivirine Promising in First-Time Treatment Takers

IAS 2011: Building a Global Strategy Towards an HIV Cure

HIV Treatment as Prevention: 96% Reduction of Sexual Transmission in HPTN 052 Study

IAS Organizers: HIV Science Breakthroughs Only Half the Battle

Traditional Risk Factors Greatest Risk for Bone Fractures

Survival Benefit Among HIV-Positive Liver, Kidney Transplant Recipients

> More Newsfeed
VIDEO
Footage from IAS 2011
Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, on treatment as prevention at IAS2011.
Michel Sidibe Giovanni Di Perri Francoise
Barre-Sinoussi
Elly Katabira Musa Ngayo Lily Telisinghe
Peter Piot Susan Kippax Julio Montaner
> More Video






[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.